Apotex fails to establish it would have obtained non-infringing perindopril from foreign third-party suppliers; original $61 …

Apotex fails to establish it would have obtained non-infringing perindopril from foreign third-party suppliers; original $61 …

Servier and its related company ADIR were successful in another chapter of patent litigation relating to perindopril (Servier’s COVERSYL): the Federal Court again dismissed Apotex’s non-infringing alternative defence, finding that Apotex would not have called on foreign third parties to manufacture perindopril to supply Apotex affiliates in the UK and Australia. The Court thereby re-affirmed […]

Global Active Pharma Ingredient Market Outlook 2018- Teva, Novartis, Pfizer, Johnson & Johnson, Mylan

Global Active Pharma Ingredient Market Outlook 2018- Teva, Novartis, Pfizer, Johnson & Johnson, Mylan

Reportsbuzz added a new latest industry research report that focuses on ”Active Pharma Ingredient market ” and provides in-depth Global Active Pharma Ingredient market analysis and future prospects of Active Pharma Ingredient market 2017. The research study covers significant data which makes the document a handy resource for managers, analysts, industry experts and other key […]

FDA's CDER Warns China- and Mexico-based Drugmakers

FDA's CDER Warns China- and Mexico-based Drugmakers

Posted 30 April 2018 | By Zachary Brennan  The US Food and Drug Administration (FDA) last week released two warning letters sent by its Center for Drug Evaluation and Research to Mexico City-based finished pharmaceutical manufacturer Degasa and Lijiang, China-based active pharmaceutical ingredient (API) manufacturer Lijiang Yinghua Biochemical and Pharmaceutical Co. For Degasa, FDA said […]

Insulin Active Pharmaceutical Ingredient Market Outlook, Opportunity And Demand Analysis, Forecast 2018-2024

Insulin Active Pharmaceutical Ingredient Market Outlook, Opportunity And Demand Analysis, Forecast 2018-2024

Market Insights Reports new study, Global Insulin Active Pharmaceutical Ingredient Market Research Report 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The global Insulin Active Pharmaceutical Ingredient market was valued at USD XXX 2017 […]

PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy

PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the successful results of long-term studies on the type of cells that will be encapsulated using its Cell-in-a-Box® technology and then combined with […]

United Therapeutics to Acquire SteadyMed for Up to $216M

United Therapeutics to Acquire SteadyMed for Up to $216M

United Therapeutics has agreed to acquire SteadyMed Therapeutics for up to $216 million, the companies said today, in a deal designed to absorb a potential competitor with which the would-be buyer has been embroiled in a legal wangle over a patent for its top-selling drug. SteadyMed’s lead product candidate is the drug–device combination Trevyent (treprostinil […]

CTech's Monday Roundup of Israeli Tech News

CTech's Monday Roundup of Israeli Tech News

Alibaba founder Jack Ma is visiting Israel. He’s scheduled meet with Prime Minister Benjamin Netanyahu. The founder and chairman of Alibaba Group Holding has landed in Israel Monday with a large delegation including senior executives from Alibaba’s subsidiaries. During his visit, Mr. Ma will meet with state officials, local companies, and investors. Read more […]

WuXi STA builds R&D site in Shanghai for APIs and intermediates

WuXi STA builds R&D site in Shanghai for APIs and intermediates

STA Pharmaceutical (WuXi STA) – a subsidiary of WuXi AppTec – has signed an investment agreement with the government of Shanghai, Jinshan District, China to build a research and development (R&D) site. The facility will be located next to the firm’s active pharmaceutical ingredient (API) and intermediates manufacturing site, adding 30,000 square meters of laboratory […]